BIOV.C -- COVID-19 and Cancer Treatment / Vaccine Development

BIOV is breaking out after a series of very promising press releases concerning their COVID-19 and cancer treatment/vaccine solutions. Still under the radar and will likely see lots of upside from here.
Comment: BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine

Vancouver, British Columbia--(Newsfile Corp. - November 11, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. Previous interim data from the study showed it possessed an excellent emerging tolerability profile with no noteworthy clinical observations or observed toxicities in the mice. When the study concluded after 6 weeks, the excellent safety and tolerability profile was maintained.

The preclinical study, which began in September 2020 and was conducted by leading independent contract research organization ("CRO") Charles River Laboratories, Inc. under contract with BioVaxys, evaluated the anti-virus immune response elicited by BVX-0320 in a controlled murine model by measuring the development of antibodies to the protein that binds the virus to human cells. Following two injections of BVX-0320 together with the immunological adjuvant, QS21, to 28 mice at four dosage levels, 96.4% developed positive antibody responses detected at week 6. As expected, prior to administering BVX-0320, all animals were antibody-negative, except for one mouse that had a borderline response. Importantly, mice that received the QS21 adjuvant without BVX-0320 developed no antibody responses.

Full-time market researcher. Not an investment advisor. Ideas are not a recommendation to buy or sell securities. For intraday alerts, weekly sector-by-sector analysis, watchlists and more, get our Premium Subscription at http://agstockpicks.com.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.